In an elderly male patient with a 5.6 cm enhancing left renal mass and a 1.3 cm hypo‑enhancing lesion in the lower pole of the right kidney, what is the appropriate work‑up and treatment plan?

Management of Bilateral Renal Masses in an Elderly Male

This elderly male requires urgent urologic consultation with a multidisciplinary approach prioritizing nephron-sparing surgery for the 5.6 cm left renal mass while characterizing the 1.3 cm right-sided lesion to preserve maximum renal function.

Immediate Work-Up

Essential Laboratory Studies

Obtain the following baseline assessments 1:

• Comprehensive metabolic panel (CMP) with creatinine and eGFR to establish CKD stage
• Complete blood count (CBC)
• Urinalysis with microscopy
• Quantify proteinuria (spot urine protein-to-creatinine ratio or 24-hour collection)

Imaging Protocol

For the 5.6 cm left mass:

• If not already done, obtain high-quality multiphase cross-sectional imaging (CT or MRI with contrast) to characterize enhancement pattern and assess for fat content 2, 1
• Chest CT for metastatic evaluation (mandatory given size >4 cm) 1
• Review abdominal imaging carefully for lymphadenopathy, venous involvement, and adrenal status

For the 1.3 cm right hypo-enhancing lesion: This requires urgent clarification as it may represent:

• Simple cyst (most likely if truly hypo-enhancing <15 HU)
• Papillary RCC (characteristically hypo-enhancing)
• Hemorrhagic cyst

MRI with and without contrast is superior to CT for lesions <1.5 cm 2, with specificity of 68.1% versus 27.7% for diagnosing RCC. MRI avoids pseudoenhancement artifact that plagues small lesions on CT and can better characterize cystic versus solid nature 2.

Renal Mass Biopsy Considerations

Biopsy the 1.3 cm right lesion before any intervention 2:

• Critical in this bilateral scenario where treatment decisions directly impact future renal function
• Up to 31.3% of masses <4 cm are benign 3
• Biopsy is particularly indicated in elderly patients with comorbidities 2
• Diagnostic rate is 80.6% for masses <4 cm, with only 0.9% significant complication rate 2
• A non-diagnostic biopsy cannot be considered evidence of benignity and may require repeat 2

The 5.6 cm left mass likely does not require biopsy given its size and enhancement characteristics make malignancy highly probable (>88% for masses >4 cm) 3.

Treatment Algorithm

For the 5.6 cm Left Renal Mass

Partial nephrectomy (PN) should be prioritized despite the size being cT1b 1, 4:

• This is an imperative indication for nephron-sparing surgery given the contralateral lesion 4
• PN is feasible for masses up to 7 cm when technically appropriate 1
• Robot-assisted or open approach preferred over laparoscopic given complexity 5
• Goal: negative margins while maximizing nephron preservation and minimizing warm ischemia time 1

Radical nephrectomy should only be considered if:

• PN is technically impossible due to hilar involvement or anatomic complexity
• Patient anatomy precludes safe partial resection even at experienced centers 1, 6

For the 1.3 cm Right Lesion

Management depends on biopsy results and MRI characterization:

If benign or simple cyst:

• No intervention required
• Routine surveillance per Bosniak classification if complex cyst

If malignant RCC:

• Active surveillance is appropriate initial management 1, 6, 4
• Growth rate averages only 3 mm/year for small masses 4, 7
• Metastatic progression occurs in only 1-2% 4
• Surveillance protocol: imaging every 3-6 months initially, then annually 5
• Intervention threshold: growth >0.4-0.5 cm/year or size >3-4 cm 5

If intervention becomes necessary:

• Thermal ablation (percutaneous cryoablation or RFA) preferred for masses <3 cm 1, 8
• Complication rate ~20%, efficacy ~90% 5
• Slightly higher local recurrence than PN but preserves maximum nephron mass 8
• PN remains option if anatomy favorable

If hypo-enhancing but indeterminate (20-70 HU):

• Lesions measuring 50+ HU have 100% sensitivity for RCC 9
• Consider dual-energy CT or MRI to definitively characterize without recall 10
• Papillary RCC characteristically shows minimal enhancement and may appear indeterminate 10

Critical Nephrology Considerations

Mandatory nephrology referral if 1, 6:

• Baseline eGFR <45 mL/min/1.73 m²
• Confirmed proteinuria present
• Diabetic with pre-existing CKD
• Expected postoperative eGFR <30 mL/min/1.73 m²

Given bilateral disease, renal functional preservation is paramount and directly impacts long-term survival, dialysis risk, and cardiovascular outcomes 1.

Age-Specific Considerations

In elderly patients, competing mortality risks must be weighed 2:

• Active surveillance for the small right lesion is strongly supported even if malignant 6, 4
• The 5.6 cm left mass requires intervention given size and oncologic risk
• Life expectancy, frailty, and comorbidities should inform surgical approach but not preclude nephron-sparing intent 1

Common Pitfalls to Avoid

1. Do not assume the 1.3 cm hypo-enhancing lesion is benign without proper characterization—papillary RCC is hypo-enhancing 10
2. Do not perform bilateral radical nephrectomy—this would necessitate dialysis
3. Do not skip biopsy of the small lesion—30% of small masses are benign and decision-modeling shows biopsy prevents unnecessary surgery 2
4. Do not use CT alone for the 1.3 cm lesion—pseudoenhancement artifact is problematic for lesions <1.5 cm 2
5. Do not delay nephrology involvement—early referral optimizes CKD management 1, 6